Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.
Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE.
Steffin DHM, et al. Among authors: wu m.
Blood. 2022 Jul 7;140(1):16-24. doi: 10.1182/blood.2022015728.
Blood. 2022.
PMID: 35325065
Free PMC article.